What did @thorvaldfetterlyfitness actually say?
The creator argues for running GHK-Cu, TB-500, BPC-157, and KPV as separate compounds rather than in a pre-mixed blend, specifically because individual dosing lets you adjust based on your needs. His example: running TB-500 at "five meg twice a week" instead of the lower daily dose baked into a bundled product. He frames this as a control-and-customization argument, not a safety argument.
He also gave a numeric comparison, claiming his approach delivers "10 milligrams of TB-500 a week" versus "7,000" from the bundled version. That second number is almost certainly a misspoken unit, likely meaning 7,000 micrograms (7 mg), not a literal separate measurement. Whether intentional or not, that comparison is confusing and deserves scrutiny.
Does the science back this up?
The general logic of individual dosing giving more flexibility is pharmacologically sound in principle. But here is the problem: none of these peptides, TB-500 (a synthetic thymosin beta-4 fragment), BPC-157, GHK-Cu, or KPV, have established therapeutic dose ranges in humans from randomized clinical trials. That makes any specific dosing claim, including his, extrapolation from animal data or anecdote.
TB-500 research in rodents and horses suggests dose-dependent effects on tissue repair and angiogenesis (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but human pharmacokinetics for subcutaneous administration have not been characterized in peer-reviewed literature. BPC-157 has shown anti-inflammatory and gastroprotective effects in animal models (Sikiric et al., 2018, Current Pharmaceutical Design), but again, no approved human dose exists. The claim that a specific weekly milligram total produces a meaningfully different anti-inflammatory response than a bundled microgram-per-day protocol is not something current evidence can confirm or deny.
What did they get wrong (or right)?
Credit where it is due: the argument that controlling individual doses gives you more flexibility is logically consistent. Compounded combination peptide products do lock you into fixed ratios, and if your goal is to adjust one peptide independently, a separate protocol is the only way to do that. That part is accurate.
What is wrong, or at least unsubstantiated, is the implication that he knows what the "right" dose of TB-500 is for anti-inflammatory response. Saying "I want more anti-inflammatory response so I run 10 mg a week" treats an unproven number as if it were a calibrated clinical target. It is not. The misspoken or unclear comparison to "7,000" also muddies the math in a way that could mislead viewers trying to replicate his stack. Additionally, none of these peptides are FDA-approved for human use in these contexts, and recommending specific weekly totals in a public video, even framed as personal preference, is the kind of content that blurs the line between experience-sharing and dosing advice.
What should you actually know?
These are research-stage compounds. TB-500 is a fragment of thymosin beta-4, a protein with real biological roles in actin regulation and tissue repair, but the leap from interesting animal data to a precise human dosing protocol is not supported by current clinical literature. BPC-157 has a growing body of preclinical research but zero completed Phase 2 or Phase 3 human trials as of 2024. GHK-Cu has human skin research behind it (Pickart and Margolina, 2018, Biomolecules) but systemic peptide use is a different matter. KPV is a tripeptide with early anti-inflammatory data in gut models.
The practical concern with any peptide stack, bundled or separate, is that you are combining compounds with unknown interaction profiles in humans. The creator frames individualized dosing as inherently safer or smarter, but there is no clinical framework to validate that either approach is safe or effective for the purposes described. If you are considering peptide therapy, that conversation belongs with a licensed provider who can review your full health picture, not a fitness influencer's prep files.